Skip to main content
Erschienen in: Strahlentherapie und Onkologie 11/2018

05.06.2018 | Original Article

Adenocarcinoma of the oesophagus: neoadjuvant chemoradiation and radical surgery

Long-term results

verfasst von: Stephanie Vitz, Holger Göbel, Bernhard Leibl, Thomas Aigner, Gerhard G. Grabenbauer, M.D.

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 11/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To retrospectively evaluate long-term treatment results following neoadjuvant chemoradiation (CRT) and radical surgery in patients with advanced adenocarcinoma (AC) of the oesophagus.

Patients and methods

Between 2005 and 2015, a total of 102 consecutive patients with a median age of 64 years (range, 44–86 years) and AC of the oesophagus were evaluated of whom 84 received a full CRT. A group of 51 patients was treated with neoadjuvant intent followed by radical surgery. A total dose of 50.4 Gy with mostly weekly paclitaxel/fluorouracil chemotherapy was administered. Six to eight weeks following CRT, a transthoracic subtotal oesophageal and proximal gastric resection was performed. Survival curves for overall survival and no evidence of disease (NED) survival (primary endpoints) were calculated according to Kaplan–Meier, and possible prognostic factors were evaluated by the log-rank test as well as by a Cox regression analysis.

Results

Median follow-up time of the surviving patients was 48 months (range, 14–134 months). Overall and NED survival rates for patients of the study group (n = 51) were 40 and 32%, respectively, at 5 years. Age (p = 0.04), ypT category (p = 0.1) and the development of distant metastases (p = 0.05) were identified as (marginally) independent prognostic variables with impact on survival. Median survival time for patients of the study group (n = 51) was 45 ± 18 months (95%CI 9–81 months). Clear resection margins were achieved in 46/51 patients (92%). Regression rates with complete regression rare residual cancer and increased number of residual cells, but predominantly fibrosis were 33, 41, and 10%, respectively. Patterns of failure revealed local with distant recurrence in 2/51 (4%), regional recurrence alone in 2/51 (4%), and distant metastases in 27/51 (53%) patients.

Conclusion

Neoadjuvant CRT in patients with AC of the oesophagus followed by thoracoabdominal surgery is a locally very effective concept. A significant tumour regression in almost 75% of the patients may stimulate prospective trials on the omission of radical surgery for some elderly patients. Due to a high rate of distant metastases further investigations in terms of effective systemic therapy may be warranted.
Literatur
4.
Zurück zum Zitat Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, Burmeister B, Kelsen D, Niedzwiecki D, Schuhmacher C, Urba S, van de Velde C, Walsh TN, Ychou M, Jensen K (2013) Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer 49(15):3149–3158. https://doi.org/10.1016/j.ejca.2013.05.029 CrossRefPubMed Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, Burmeister B, Kelsen D, Niedzwiecki D, Schuhmacher C, Urba S, van de Velde C, Walsh TN, Ychou M, Jensen K (2013) Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer 49(15):3149–3158. https://​doi.​org/​10.​1016/​j.​ejca.​2013.​05.​029 CrossRefPubMed
5.
Zurück zum Zitat Kumagai K, Rouvelas I, Tsai JA, Mariosa D, Lind PA, Lindblad M, Ye W, Lundell L, Schuhmacher C, Mauer M, Burmeister BH, Thomas JM, Stahl M, Nilsson M (2015) Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis. Eur J Surg Oncol 41(3):282–294. https://doi.org/10.1016/j.ejso.2014.11.039 CrossRefPubMed Kumagai K, Rouvelas I, Tsai JA, Mariosa D, Lind PA, Lindblad M, Ye W, Lundell L, Schuhmacher C, Mauer M, Burmeister BH, Thomas JM, Stahl M, Nilsson M (2015) Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis. Eur J Surg Oncol 41(3):282–294. https://​doi.​org/​10.​1016/​j.​ejso.​2014.​11.​039 CrossRefPubMed
11.
Zurück zum Zitat Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16(9):1090–1098. https://doi.org/10.1016/s1470-2045(15)00040-6 CrossRefPubMed Shapiro J, van Lanschot JJB, Hulshof M, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16(9):1090–1098. https://​doi.​org/​10.​1016/​s1470-2045(15)00040-6 CrossRefPubMed
12.
Zurück zum Zitat Stahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, Wilke H, Budach W (2017) Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial. Eur J Cancer 81:183–190. https://doi.org/10.1016/j.ejca .2017.04.027CrossRefPubMed Stahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, Wilke H, Budach W (2017) Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial. Eur J Cancer 81:183–190. https://​doi.​org/​10.​1016/​j.​ejca .2017.04.027CrossRefPubMed
13.
Zurück zum Zitat Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A, Budach W, Wilke H (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27(6):851–856. https://doi.org/10.1200/jco.2008.17.0506 CrossRefPubMed Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A, Budach W, Wilke H (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27(6):851–856. https://​doi.​org/​10.​1200/​jco.​2008.​17.​0506 CrossRefPubMed
15.
Zurück zum Zitat Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW (2005) Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23(6):1237–1244. https://doi.org/10.1200/jco.2005.01.305 CrossRefPubMed Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, Janjan N, Feig B, Faust J, Yao JC, Nivers R, Morris J, Pisters PW (2005) Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23(6):1237–1244. https://​doi.​org/​10.​1200/​jco.​2005.​01.​305 CrossRefPubMed
18.
Zurück zum Zitat Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73(11):2680–2686CrossRefPubMed Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G et al (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73(11):2680–2686CrossRefPubMed
19.
Zurück zum Zitat Klevebro F, Alexandersson von Dobeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, Hatlevoll I, Glenjen NI, Lind P, Tsai JA, Lundell L, Nilsson M (2016) A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 27(4):660–667. https://doi.org/10.1093/annonc/mdw010 CrossRefPubMed Klevebro F, Alexandersson von Dobeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, Hatlevoll I, Glenjen NI, Lind P, Tsai JA, Lundell L, Nilsson M (2016) A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 27(4):660–667. https://​doi.​org/​10.​1093/​annonc/​mdw010 CrossRefPubMed
20.
Zurück zum Zitat Goense L, van der Sluis PC, van Rossum PSN, van der Horst S, Meijer GJ, Haj MN, van Vulpen M, Mook S, Ruurda JP, van Hillegersberg R (2017) Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: a propensity score-matched analysis comparing toxicity, pathologic outcome, and survival. J Surg Oncol 115(7):812–820. https://doi.org/10.1002/jso.24596 CrossRefPubMed Goense L, van der Sluis PC, van Rossum PSN, van der Horst S, Meijer GJ, Haj MN, van Vulpen M, Mook S, Ruurda JP, van Hillegersberg R (2017) Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: a propensity score-matched analysis comparing toxicity, pathologic outcome, and survival. J Surg Oncol 115(7):812–820. https://​doi.​org/​10.​1002/​jso.​24596 CrossRefPubMed
21.
Zurück zum Zitat Munch S, Habermehl D, Agha A, Belka C, Combs SE, Eckel R, Friess H, Gerbes A, Nussler NC, Schepp W, Schmid RM, Schmitt W, Schubert-Fritschle G, Weber B, Werner J, Engel J (2018) Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma: a population-based evaluation of the Munich Cancer Registry. Strahlenther Onkol 194(2):125–135. https://doi.org/10.1007/s00066-017-1225-7 CrossRefPubMed Munch S, Habermehl D, Agha A, Belka C, Combs SE, Eckel R, Friess H, Gerbes A, Nussler NC, Schepp W, Schmid RM, Schmitt W, Schubert-Fritschle G, Weber B, Werner J, Engel J (2018) Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma: a population-based evaluation of the Munich Cancer Registry. Strahlenther Onkol 194(2):125–135. https://​doi.​org/​10.​1007/​s00066-017-1225-7 CrossRefPubMed
22.
Zurück zum Zitat van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084. https://doi.org/10.1056/NEJMoa1112088 CrossRefPubMed van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084. https://​doi.​org/​10.​1056/​NEJMoa1112088 CrossRefPubMed
23.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20. https://doi.org/10.1056/NEJMoa055531 CrossRefPubMed Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20. https://​doi.​org/​10.​1056/​NEJMoa055531 CrossRefPubMed
26.
Zurück zum Zitat Lagarde SM, Navidi M, Gisbertz SS, van Laarhoven HW, Sumpter K, Meijer SL, Disep B, Immanuel A, Griffin SM, van Berge Henegouwen MI (2016) Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy. Br J Surg 103(12):1658–1664. https://doi.org/10.1002/bjs.10226 CrossRefPubMed Lagarde SM, Navidi M, Gisbertz SS, van Laarhoven HW, Sumpter K, Meijer SL, Disep B, Immanuel A, Griffin SM, van Berge Henegouwen MI (2016) Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy. Br J Surg 103(12):1658–1664. https://​doi.​org/​10.​1002/​bjs.​10226 CrossRefPubMed
29.
Zurück zum Zitat Mokdad AA, Yopp AC, Polanco PM, Mansour JC, Reznik SI, Heitjan DF, Choti MA, Minter RR, Wang SC, Porembka MR (2018) Adjuvant chemotherapy vs postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer: a propensity score-matched analysis. JAMA Oncol 4(1):31–38. https://doi.org/10.1001/jamaoncol.2017.2805 CrossRefPubMed Mokdad AA, Yopp AC, Polanco PM, Mansour JC, Reznik SI, Heitjan DF, Choti MA, Minter RR, Wang SC, Porembka MR (2018) Adjuvant chemotherapy vs postoperative observation following preoperative chemoradiotherapy and resection in gastroesophageal cancer: a propensity score-matched analysis. JAMA Oncol 4(1):31–38. https://​doi.​org/​10.​1001/​jamaoncol.​2017.​2805 CrossRefPubMed
Metadaten
Titel
Adenocarcinoma of the oesophagus: neoadjuvant chemoradiation and radical surgery
Long-term results
verfasst von
Stephanie Vitz
Holger Göbel
Bernhard Leibl
Thomas Aigner
Gerhard G. Grabenbauer, M.D.
Publikationsdatum
05.06.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 11/2018
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-018-1320-4

Weitere Artikel der Ausgabe 11/2018

Strahlentherapie und Onkologie 11/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.